作为协议的一部分,葛兰素史克不承认存在不当行为,并在一份声明中表示,“没有一致或可靠的证据”表明该药的活性成分雷尼替丁(ranitidine ...
Morgan Stanley previously suggested the Zantac cases could cost GSK as much as $30bn to settle, although other analysts have since put the figure at somewhere between $2bn and $8bn. Concerns over ...
葛兰素史克 在美国州法院Zantac案件中达成高达22亿美元的和解协议。 葛兰素史克公司周三表示,已与10家原告公司达成协议,这些公司占美国州法院 ...
UK pharmaceutical giant GSK says it will pay as much as $2.2bn (£1.68bn) to settle thousands of cases in US courts over claims that a discontinued version of its heartburn drug Zantac caused cancer.
ranitidine, caused cancer. A research note by analysts at Morgan Stanley in 2022 said the action could cost the industry as much as £35billion, with GSK facing liabilities of between £2 ...
The discontinued version of the drug, Zantac, had triggered 80,000 lawsuits ... get this monkey off its back almost regardless of the cost”. Earlier estimates by Morgan Stanley suggested the ...
GSK launched Zantac in 1981 and it was first approved for sale in the US in 1983 as a prescription medication. It went on to become the world's best-selling drug, with annual sales in excess of $1bn.
GSK said total sales fell by two per cent in the third quarter Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance and ...
Delaware’s top court is set to hear an appeal from GSK and other pharmaceutical giants to throw out over 70,000 lawsuits ...
GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...
Corrects headline to say 'settlements' instead of 'settlement' British pharmaceutical company GSK said Wednesday it has agreed to pay $2.3 billion in the United States to put an end to lawsuits ...
GSK declared a third-quarter dividend of 15.00 pence per share, unchanged from the second quarter, but up 7.1% from 14.00p per share last year. It continues to expect a total dividend of 60.00p per ...